VG-3927 | ALZFORUM
Aug 5, 2024 · VG-3927 is a brain-penetrant, small-molecule agonist of the TREM2 receptor on microglia. TREM2 activation stimulates proliferation and phagocytic function of microglia, …
FDA Removes Partial Clinical Hold on VG-3927 for Microglial …
Jan 6, 2025 · Key Takeaways The FDA lifted a partial clinical hold on Vigil Neuroscience's phase 1 trial of VG-3927 for Alzheimer's disease. VG-3927, a TREM2 agonist, showed safety, …
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical ...
2 days ago · VG-3927 is designed to enhance protective microglial responses to aggregated amyloid and tau without increasing inflammation. In contrast to antibody TREM2 agonists, VG …
Vigil Neuroscience Announces FDA Has Removed Partial
Sep 17, 2024 · Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial …
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical ...
1 day ago · - Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s …
Vigil Neuroscience Announces Update on its Small Molecule
Sep 8, 2023 · Vigil’s highly active, selective, and brain-penetrant small molecule TREM2 agonist, VG-3927, is designed to act as a molecular glue that potentiates the TREM2 signaling …
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early
1 day ago · Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s …
Vigil Neuroscience Announces FDA Has Removed Partial Clinical
Sep 17, 2024 · Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial …
Vigil Neuroscience Announces First Participant Dosed in Phase 1 ...
Oct 17, 2023 · Vigil’s highly active, selective, and brain-penetrant small molecule TREM2 agonist, VG-3927, is designed to act as a molecular glue that potentiates the TREM2 signaling …
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG ...
Mar 6, 2024 · Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial …
- Some results have been removed